• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu

Vaccines

Record of E-mail Communication 2 - July 14, 2009

 

RECORD OF E-MAIL COMMUNICATION 

Submission Type: Original Application Submission ID: 125347/0 Office: OVRR 

Product: 
Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) 

Applicant: 
GlaxoSmithKline Biologicals 

Telecon Date/Time: 14-JUL-2009 10:00 AM Initiated by FDA? Yes 
Telephone Number: 

Communication Category(s): 
Labeling via FAX/e-mail 

Author: JASON HUMBERT 

Telecon Summary: 
Additional comments related to the revised PI submitted July 10, 2009 

FDA Participants: Jason Humbert 

Non-FDA Participants: Elisa Harkins, GSK 

Telecon Body: The following two comments were conveyed to GSK via e-mail: 

1. Page 7, Under Section 11 Description, Lines 164-171: We recommend the following changes: 

...The toxoid toxin, prepared from Clostridium tetani grown in a semi-synthetic medium, is detoxified and purified. The capsular polysaccharide is covalently bound to the inactivated tetanus toxoid. After purification, the conjugate is lyophilized in the presence of lactose as a stabilizer. The diluent for HIBERIX is a sterile saline solution (0.9% sodium chloride) supplied in prefilled TIP-LOK syringes. 

When HIBERIX is reconstituted with the accompanying saline diluent, each 0.5-mL dose is formulated to contain 10 mcg of purified capsular polysaccharide conjugated to approximately 25 mcg of inactivated tetanus toxoid, and 12.6 mg of lactose. 

2. Page 9, Line 247: Please delete “-1035”.

 

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002